Clinical Trial

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-12
Trial Details
NCT Number NCT07628127
Lead Sponsor Verdiva Bio Dev Limited
Conditions Obesity, Overweight
Enrollment 336 participants
Start Date 2026-07-06
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-11